Audience Discussion: Modality Debate – Autologous vs Allogeneic vs In Vivo
9:00 am - Thursday 3rd December 2026
- Debating which platform will dominate the autoimmune cell therapy landscape long-term
- Evaluating trade-offs between manufacturing control, patient convenience, safety, and efficacy
- Assessing whether ex vivo autologous approaches represent a transitional technology or enduring solution
